| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02076815 | Essential Thrombocythemia | Drug: Anagrelide retard|Drug: Thromboreductin | AOP Orphan Pharmaceuticals AG | Phase 3 | 2014-02-01 | 2015-07-27 |
| NCT01352585 | Essential Thrombocythaemia | Drug: Anagrelide hydrochloride | Shire | | 2011-07-01 | 2014-06-27 |
| NCT02125318 | Thrombocytosis|Myeloproliferative Neoplasms | Drug: Anagrelide CR | Galena Biopharma, Inc. | Phase 2 | 2014-05-01 | 2017-02-23 |
| NCT00648765 | Healthy | Drug: Anagrelide Hydrochloride Capsules 1 mg|Drug: Agrylin Capsules 1 mg | Mylan Pharmaceuticals | Phase 1 | 2003-01-01 | 2008-03-31 |
| NCT00648024 | Healthy | Drug: Anagrelide Hydrochloride Capsules 1 mg|Drug: Agrylin Capsules 1 mg | Mylan Pharmaceuticals | Phase 1 | 2003-01-01 | 2008-03-31 |
| NCT01230775 | Essential Thrombocythaemia | Drug: Anagrelide retard|Drug: Placebo | AOP Orphan Pharmaceuticals AG | Phase 3 | 2010-12-01 | 2016-05-25 |
| NCT01552928 | Healthy | Drug: Anagrelide 0.5 mg|Drug: Anagrelide 2.5 mg|Drug: Moxifloxacin|Drug: Placebo | Shire | Phase 1 | 2012-03-01 | 2014-03-12 |
| NCT00413634 | Essential Thrombocythaemia | Drug: anagrelide hydrochloride | Shire | Phase 2 | 2006-08-01 | 2014-06-06 |
| NCT01065038 | Essential Thrombocythaemia | Drug: Anagrelide|Drug: Hydroxyurea | AOP Orphan Pharmaceuticals AG | Phase 3 | 2002-09-01 | 2010-10-05 |
| NCT00202644 | Thrombocythemia, Hemorrhagic | Drug: Anagrelide|Drug: Hydroxyurea | Shire | Phase 4 | 2006-01-01 | 2016-02-18 |
| NCT01467661 | Essential Thrombocythemia (ET) | Drug: SPD422 (anagrelide hydrochloride) | Shire | Phase 3 | 2011-11-01 | 2016-06-22 |
| NCT00567502 | Thrombocythemia, Essential | | Shire | | 2005-05-01 | 2015-10-15 |
| NCT01192347 | Essential Thrombocythemia | | Shire | | 2010-09-01 | 2014-02-14 |
| NCT01214915 | Thrombocythemia, Essential | Drug: Anagrelide Hydrochloride | Shire | Phase 3 | 2010-11-01 | 2013-09-27 |
| NCT02962388 | Essential Thrombocythemia | Drug: Anagrelide|Drug: Ruxolitinib (JAKAVI庐)|Drug: IFN/ PegIFN | French Innovative Leukemia Organisation|Novartis Pharmaceuticals | Phase 2|Phase 3 | 2017-01-01 | 2017-01-16 |
| NCT02577926 | Polycythemia Vera (PV)|Essential Thrombocythemia (ET) | Drug: Ruxolitinib|Drug: BAT | RWTH Aachen University|Novartis | Phase 3 | 2015-10-01 | 2016-09-07 |
| NCT02038036 | Polycythemia Vera | Drug: Best Available Therapy|Drug: ruxolitinib | Novartis Pharmaceuticals|Novartis | Phase 3 | 2014-03-25 | 2017-03-07 |
| NCT01668173 | Myeloproliferative Neoplasms | Drug: AUY922 | Memorial Sloan Kettering Cancer Center|Novartis | Phase 2 | 2012-08-01 | 2016-04-11 |
| NCT02101268 | Primary Myelofibrosis (PMF)|Post-polycythemia Vera (Post-PV)|Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) | Drug: Momelotinib|Drug: Best Available Therapy (BAT) | Gilead Sciences | Phase 3 | 2014-06-01 | 2017-02-13 |
| NCT02252159 | Polycythemia Vera | | Incyte Corporation | | 2014-07-01 | 2017-02-28 |
| NCT01243944 | Polycythemia Vera | Drug: ruxolitinib tablets|Other: Best Available Therapy (BAT) | Incyte Corporation|Novartis Pharmaceuticals | Phase 3 | 2010-10-01 | 2016-09-21 |
| NCT00481052 | Chronic Myeloid Leukemia | Drug: Nilotinib | Gruppo Italiano Malattie EMatologiche dell'Adulto | Phase 2 | 2007-06-01 | 2016-10-24 |
